-
Alexopoulou A, Dourakis S P, Pandelidaki H, Archimandritis A J, Karayiannis P, 2006: Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine[J]. J Med Virol, 78, 1043-1046. doi: 10.1002/(ISSN)1096-9071
-
Awerkiew S, Daumer M, Reiser M, Wend U C, Pfister H, Kaiser R, Willems W R, Gerlich W H, 2007: Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient[J]. J Clin Virol, 38, 83-86. doi: 10.1016/j.jcv.2006.10.006
-
Carman W F, Korula J, Wallace L, MacPhee R, Mimms L, Decker R, 1995: Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA[J]. Lancet, 345, 1406-1407. doi: 10.1016/S0140-6736(95)92599-6
-
Dahlen D D, Broudy V C, Drachman J G, 2003: Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs[J]. Blood, 102, 102-108. doi: 10.1182/blood-2002-11-3468
-
Ferreira R, Carvalheiro J, Torres J, Fernandes A, Giestas S, Mendes S, Agostinho C, Campos M J, 2012: Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: A case report and literature review[J]. Saudi J Gastroenterol, 18, 277-281. doi: 10.4103/1319-3767.98436
-
Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N, Sueoka E, 2009: Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier[J]. Ann Oncol, 20, 2013-2017. doi: 10.1093/annonc/mdp230
-
Iannitto E, Minardi V, Calvaruso G, Mule A, Ammatuna E, Di Trapani R, Ferraro D, Abbadessa V, Craxi A, Di Stefano R, 2005: Hepatitis B virus reactivation and alemtuzumab therapy[J]. Eur J Haematol, 74, 254-258. doi: 10.1111/ejh.2005.74.issue-3
-
Lee I C, Huang Y H, Chu C J, Lee P C, Lin H C, Lee S D, 2010: Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma[J]. J Chin Med Assoc, 73, 156-160. doi: 10.1016/S1726-4901(10)70031-9
-
Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M, 2010: Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma[J]. Cancer, 116, 4769-4776. doi: 10.1002/cncr.v116:20
-
Mele A, Tancredi F, Romano L, Giuseppone A, Colucci M, Sangiuolo A, Lecce R, Adamo B, Tosti M E, Taliani G, Zanetti A R, 2001: Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy[J]. J Infect Dis, 184, 905-908. doi: 10.1086/jid.2001.184.issue-7
-
Moerman B, Moons V, Sommer H, Schmitt Y, Stetter M, 2004: Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays[J]. Clin Lab, 50, 159-162.
-
Nainan O V, Khristova M L, Byun K, Xia G, Taylor P E, Stevens C E, Margolis H S, 2002: Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection[J]. J Med Virol, 68, 319-327. doi: 10.1002/(ISSN)1096-9071
-
Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M, Asaka M, 2005: Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection[J]. Transplantation, 79, 616-619. doi: 10.1097/01.TP.0000151661.52601.FB
-
Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde K H, Neuhaus P, Gerken G, 1998: Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation[J]. Hepatology, 27, 254-263. doi: 10.1002/hep.v27:1
-
Sarrecchia C, Cappelli A, Aiello P, 2005: HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb[J]. J Infect Chemother, 11, 189-191. doi: 10.1007/s10156-005-0385-Z
-
Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, Matsuura B, Kajiwara T, Masumoto T, Horiike N, Onji M, 2006: Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab[J]. Intern Med, 45, 721-724. doi: 10.2169/internalmedicine.45.1590
-
Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, Kanamori H, Tanaka J, Asaka M, Imamura M, Masauzi N, 2004: Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy[J]. Leuk Lymphoma, 45, 627-629. doi: 10.1080/1042819031000151923
-
Westhoff T H, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer J H, Zidek W, Gerlich W H, Thiel E, 2003: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy[J]. Blood, 102, 1930-. doi: 10.1182/blood-2003-05-1403
-
Wu C, Shi H, Wang Y, Lu M, Xu Y, Chen X, 2012: A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy[J]. Virol Sin, 27, 368-371. doi: 10.1007/s12250-012-3284-3
-
Yamagata M, Murohisa T, Tsuchida K, Okamoto Y, Tsunoda S, Nakamura M, Kusano K, Majima Y, Kuniyoshi T, Iijima M, Sugaya H, Hiraishi H, 2007: Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab[J]. Leuk Lymphoma, 48, 431-433. doi: 10.1080/10428190601059704
-
Yeo W, Chan T C, Leung N W, Lam W Y, Mo F K, Chu M T, Chan H L, Hui E P, Lei K I, Mok T S, Chan P K, 2009: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J]. J Clin Oncol, 27, 605-611. doi: 10.1200/JCO.2008.18.0182
-
Zhang J M, Xu Y, Wang X Y, Yin Y K, Wu X H, Weng X H, Lu M, 2007: Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection[J]. Clin Infect Dis, 44, 1161-1169. doi: 10.1086/513200